The nation of Zimbabwe has turned down a substantial American healthcare agreement valued at $367m (£272m) spanning five years over Washington's insistence on sensitive data.
This move became public after a official document dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesman later stated that the United States was requesting biological samples for research and commercial purposes while was not willing to guarantee the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had donated more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for further dialogue to secure a agreement acceptable to both sides so the nation's critical HIV programme can proceed.
Broader Implications
This development comes after a comparable case in Kenya, where a court halted a related deal with the US after concerns were filed about the security of citizens' medical information.
Since resuming office recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had managed aid for the US government, but Trump argued its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to enhance openness and responsibility.
According to statements, 16 nations in Africa have to date agreed to these new agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The money for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration might have yielded significant benefits for Zimbabwean communities, especially the 1.2 million presently on HIV treatment through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information indefinitely, without any corresponding assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Effectively, our country would provide the raw materials for medical research without any certainty that the end products would be available to our citizens if a future pandemic arise."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were disrupting structures already established through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to deal with potential pandemics.
"This system is designed to ensure that when a nation contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome continued dialogue with our American counterparts on how future collaboration could be designed in a way that honours the sovereignty and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the official position, but urged that negotiations need to persist considering a large portion of the country's Aids initiatives depended on foreign aid.
"In cases where specific concerns arise, such as those involving information security or implementation frameworks, these can often be addressed via technical clarification and negotiated safeguards," the group commented.
This impasse emphasises the complex debate between accepting vital international aid and safeguarding national sovereignty in an increasingly data-driven world.